Advertisement

Hypopigmenting Disorders

  • Joni M. Mazza
  • Candrice Heath
  • Nanette B. Silverberg
Chapter

Abstract

Loss of pigment, whether hypopigmentation, depigmentation, or dyspigmentation, is a common complaint in pediatric patients of color. Childhood loss of pigment can be divided into localized or generalized variants, congenital (under the age of 2 years at onset) or acquired, and by etiology. The following chapter identifies strategies to identify causes of pigment loss in children and reviews specific diagnoses commonly noted and pertinent to or with nuances in children of color worldwide.

Keywords

Loss of pigment Hypopigmentation Depigmentation Dyspigmentation Localized variants Generalized variants Congenital Etiology 

Notes

Conflict of Interest 

The authors report no relevant conflicts of interest in this work.

References

  1. 1.
    Sori T, Nath AK, Thappa DM, Jaisankar TJ. Hypopigmentary disorders in children in South India. Indian J Dermatol. 2011;56(5):546–9.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Kawada A, Suzuki T. Piebaldism. J Dermatol. 2013;40(5):330–5.PubMedGoogle Scholar
  3. 3.
    Shih IH, Lin JY, Chen CH, Hong HS. A birthmark survey in 500 newborns: clinical observation in two northern Taiwan medical center nurseries. Chang Gung Med J. 2007;30(3):220–5.PubMedGoogle Scholar
  4. 4.
    Lio PA. Little white spots: an approach to hypopigmented macules. Arch Dis Child Educ Pract Ed. 2008;93(3):98–102.PubMedGoogle Scholar
  5. 5.
    Xu AE, Huang B, Li YW, Wang P, Shen H. Clinical, histopathological and ultrastructural characteristics of naevus depigmentosus. Clin Exp Dermatol. 2008;33(4):400–5.PubMedGoogle Scholar
  6. 6.
    Tey HL. A practical classification of childhood hypopigmentation disorders. Acta Derm Venereol. 2010;90(1):6–11.PubMedGoogle Scholar
  7. 7.
    Silverberg NB. Evaluation of hypopigmentation on children. Cutis in pressGoogle Scholar
  8. 8.
    van Geel N, Speeckaert M, Chevolet I, De Schepper S, Lapeere H, Boone B, Speeckaert R. Hypomelanoses in children. J Cutan Aesthet Surg. 2013;6(2):65–72.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Dessinioti C, Stratigos AJ, Rigopoulos D, Katsambas AD. A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes. Exp Dermatol. 2009;18(9):741–9.PubMedGoogle Scholar
  10. 10.
    Silverberg NB. Pediatric dermatology in children of color. Access Dermatology, posted 17 Aug 2010Google Scholar
  11. 11.
    Sharma P, Pai HS, Kamath MM. Nevus depigmentosus affecting the iris and skin: a case report. J Eur Acad Dermatol Venereol. 2008;22(5):634–5.PubMedGoogle Scholar
  12. 12.
    Park ES, Na JI, Kim SO, Huh CH, Youn SW, Park KC. Application of a pigment measuring device – Mexameter – for the differential diagnosis of vitiligo and nevus depigmentosus. Skin Res Technol. 2006;12(4):298–302.PubMedGoogle Scholar
  13. 13.
    Pan ZY, Yan F, Zhang ZH, Zhang QA, Xiang LH, Zheng ZZ. In vivo reflectance confocal microscopy for the differential diagnosis between vitiligo and nevus depigmentosus. Int J Dermatol. 2011;50(6):740–5.PubMedGoogle Scholar
  14. 14.
    Jindal R, Jain A, Gupta A, Shirazi N. Ash-leaf spots or naevus depigmentosus: a diagnostic challenge. BMJ Case Rep. 2013;2013. pii:bcr2012007008.Google Scholar
  15. 15.
    Kar BR. Nevus depigmentosus treated with suction blister grafting: follow-up after 10 years. Indian J Dermatol. 2013;58(2):158.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Mulekar SV, Al Issa A, Al Eisa A. Nevus depigmentosus treated by melanocyte-keratinocyte transplantation. J Cutan Aesthet Surg. 2011;4(1):29–32.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Kim Y, Lee KY, Park YK. Use of the 308-nm excimer laser for nevus depigmentosus: a promising treatment for either nevus depigmentosus or vitiligo. J Dermatol. 2007;34(3):217–8.Google Scholar
  18. 18.
    Lee DJ, Kang HY. Is spontaneous disappearance of nevus depigmentosus possible? Ann Dermatol. 2012;24(1):109–11.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Setty SR, Tenza D, Sviderskaya EV, Bennett DC, Raposo G, Marks MS. Cell-specific ATP7A transport sustains copper-dependent tyrosinase activity in melanosomes. Nature. 2008;454(7208):1142–6.PubMedGoogle Scholar
  20. 20.
    Møller LB, Lenartowicz M, Zabot MT, Josiane A, Burglen L, Bennett C, Riconda D, Fisher R, Janssens S, Mohammed S, Ausems M, Tümer Z, Horn N, Jensen TG. Clinical expression of Menkes disease in females with normal karyotype. Orphanet J Rare Dis. 2012;7:6. doi: 10.1186/1750-1172-7-6.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Lorette G, Toutain A, Barthes M, Saliba E, Georgesco G, Moraine C. Menkes syndrome. An unusual pigmentation anomaly in a mother and three sisters. Ann Pediatr (Paris). 1992;39(7):453–6.Google Scholar
  22. 22.
    Patrizi A, Neri I, Fiorentini C, Bonci A, Ricci G. Lichen striatus: clinical and laboratory features of 115 children. Pediatr Dermatol. 2004;21(3):197–204.PubMedGoogle Scholar
  23. 23.
    Peramiquel L, Baselga E, Dalmau J, Roé E, del Mar Campos M, Alomar A. Lichen striatus: clinical and epidemiological review of 23 cases. Eur J Pediatr. 2006;165(4):267–9.PubMedGoogle Scholar
  24. 24.
    Mittal R, Khaitan BK, Ramam M, Verma KK, Manchanda M. Multiple lichen striatus – an unusual presentation. Indian J Dermatol Venereol Leprol. 2001;67(4):204.PubMedGoogle Scholar
  25. 25.
    Taniguchi Abagge K, Parolin Marinoni L, Giraldi S, Carvalho VO, de Oliveira Santini C, Favre H. Lichen striatus: description of 89 cases in children. Pediatr Dermatol. 2004;21(4):440–3.PubMedGoogle Scholar
  26. 26.
    Palleschi GM, D’Erme AM, Lotti T. Lichen striatus and nail involvement: truly rare or question of time? Int J Dermatol. 2012;51(6):749–50.PubMedGoogle Scholar
  27. 27.
    Mu EW, Abuav R, Cohen BA. Facial lichen striatus in children: retracing the lines of blaschko. Pediatr Dermatol. 2013;30(3):364–6.PubMedGoogle Scholar
  28. 28.
    Mun JH, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS, Kim MB. Lichen striatus occurring after allogenic peripheral blood stem cell transplantation in an adult with aplastic anemia. Ann Dermatol. 2012;24(1):87–9.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Kim GW, Kim SH, Seo SH, Jung DS, Ko HC, Kim MB, Kwon KS. Lichen striatus with nail abnormality successfully treated with tacrolimus ointment. J Dermatol. 2009;36(11):616–7.PubMedGoogle Scholar
  30. 30.
    Youssef SM, Teng JM. Effective topical combination therapy for treatment of lichen striatus in children: a case series and review. J Drugs Dermatol. 2012;11(7):872–5.PubMedGoogle Scholar
  31. 31.
    Park JY, Kim YC. Lichen striatus successfully treated with photodynamic therapy. Clin Exp Dermatol. 2012;37(5):570–2.PubMedGoogle Scholar
  32. 32.
    Spitz JL. Genodermatoses: a clinical guide to genetic skin disorders. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.Google Scholar
  33. 33.
    Paller A, Mancini AJ. Hurwitz clinical pediatric dermatology textbook. 4th ed. Philadelphia, PA: Elsevier Saunders; 2011.Google Scholar
  34. 34.
    Ruiz-Maldonado R. Hypomelanotic conditions of the newborn and infant. Dermatol Clin. 2007;25:373–82.PubMedGoogle Scholar
  35. 35.
    Koono P, Silm H. Waardenburg syndrome. J Eur Acad Dermatol Venereol. 2001;15:330–3.Google Scholar
  36. 36.
    Kujat A, Veith VP, Faber R, Froster UG. Prenatal diagnosis and genetic counseling in a case of spina bifida in a family with Waardenburg syndrome type I. Fetal Diagn Ther. 2007;22(2):155–8. Epub 2006 Nov 28.PubMedGoogle Scholar
  37. 37.
    Richards KA, Fukai K, Oiso N, et al. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol. 2001;44:288–92.PubMedGoogle Scholar
  38. 38.
    Matsunaga H, Tanioka M, Utani A, Miyachi Y. Familial case of piebaldism with regression of white forelock. Clin Exp Dermatol. 2008;33(4):511–2.PubMedGoogle Scholar
  39. 39.
    Janjua S, Khachemoune A, Guldbakke KK. Piebaldism: a case report and a concise review of the literature. Cutis. 2007;80:411–4.PubMedGoogle Scholar
  40. 40.
    Njoo MD, Nieuweboer-Krobotova L, Westerhof W. Repigmentation of leucodermic defects in piebaldism by dermabrasion and thin split-thickness skin grafting in combination with minigrafting. Br J Dermatol. 1998;139(5):829–33.PubMedGoogle Scholar
  41. 41.
    Garg T, Khaitan BK, Manchanda Y. Autologous punch grafting for repigmentation in piebaldism. J Dermatol. 2003;30(11):849–50.PubMedGoogle Scholar
  42. 42.
    Guerra L, Primavera G, Raskovic D, et al. Permanent repigmentation of piebaldism by erbium:YAG laser and autologous cultured epidermis. Br J Dermatol. 2004;150(4):715–21.PubMedGoogle Scholar
  43. 43.
    Kamaraj B, Purohit R. Mutational analysis of oculocutaneous albinism: a compact review. Biomed Res Int. 2014;2014:905472.Google Scholar
  44. 44.
    Perry P, Silverberg NB. Cutaneous malignancy in albinism. Cutis. 2001;67:427–30.Google Scholar
  45. 45.
    Onojafe IF, Adams DR, Simeonov DR, et al. Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism. J Clin Invest. 2011;121(10):3914–23.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Manga P, Orlow SJ. Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinism. J Clin Invest. 2011;121(10):3828–31.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Cruz-Inigo AE, Ladizinski B, Sethi A. Albinism in Africa: stigma, slaughter and awareness campaigns. Dermatol Clin. 2011;29(1):79–87. doi: 10.1016/j.det.2010.08.015.PubMedGoogle Scholar
  48. 48.
    Carmona-Rivera C, Golas G, Hess RA, Cardillo ND, Martin EH, O’Brien K, Tsilou E, Gochuico BR, White JG, Huizing M, Gahl WA. Clinical, molecular, and cellular features of non-Puerto Rican Hermansky-Pudlak syndrome patients of Hispanic descent. J Invest Dermatol. 2011;131(12):2394–400.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Guillet G, Helenon R, Gauthier Y, Surleve-Bazeille JE, Plantin P, Sassolas B. Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol. 1988;15(5):286–9.PubMedGoogle Scholar
  50. 50.
    Westerhof W, Relyveld GN, Kingswijk MM, de Man P, Menke HE. Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis. Arch Dermatol. 2004;140(2):210–4.PubMedGoogle Scholar
  51. 51.
    Relyveld GN, Menke HE, Westerhof W. Progressive macular hypomelanosis: an overview. Am J Clin Dermatol. 2007;8(1):13–9. Review.PubMedGoogle Scholar
  52. 52.
    Kim YJ, Lee DY, Lee JY, Yoon TY. Progressive macular hypomelanosis showing excellent response to oral isotretinoin. J Dermatol. 2012;39(11):937–8. doi: 10.1111/j.1346-8138.2012.01605.x. Epub 2012 Jun 23.PubMedGoogle Scholar
  53. 53.
    Halder RM, Grimes PE, Cowan CA, Enterline JA, Chakrabarti SG, Kenney Jr JA. Childhood vitiligo. J Am Acad Dermatol. 1987;16:948–54.PubMedGoogle Scholar
  54. 54.
    Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–12.PubMedGoogle Scholar
  55. 55.
    Wang X, Du J, Wang T, Zhou C, Shen Y, Ding X, Tian S, Liu Y, Peng G, Xue S, Zhou J, Wang R, Meng X, Pei G, Bai Y, Liu Q, Li H, Zhang J. Prevalence and clinical profile of vitiligo in China: a community-based study in six cities. Acta Derm Venereol. 2013;93(1):62–5.PubMedGoogle Scholar
  56. 56.
    Yamamah GA, Emam HM, Abdelhamid MF, et al. Epidemiologic study of dermatologic disorders among children in South Sinai, Egypt. Int J Dermatol. 2012;51:1180–5.PubMedGoogle Scholar
  57. 57.
    Komba EV, Mgonda YM. The spectrum of dermatological disorders among primary school children in Dar es Salaam. BMC Public Health. 2010;10:765.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Krüger C, Panske A, Schallreuter KU. Disease-related behavioral patterns and experiences affect quality of life in children and adolescents with vitiligo. Int J Dermatol. 2014;53(1):43–50.PubMedGoogle Scholar
  59. 59.
    Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet. 2012;44:676–80.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Agarwal S, Gupta S, Ojha A, Sinha R. Childhood vitiligo: clinicoepidemiologic profile of 268 children from the Kumaun region of Uttarakhand, India. Pediatr Dermatol. 2013;30(3):348–53.PubMedGoogle Scholar
  61. 61.
    Alissa A, Al Eisa A, Huma R, Mulekar S. Vitiligo-epidemiological study of 4134 patients at the National Center for Vitiligo and Psoriasis in Central Saudi Arabia. Saudi Med J. 2011;32(12):1291–6.PubMedGoogle Scholar
  62. 62.
    Silva de Castro CC, do Nascimento LM, Olandoski M, Mira MT. A pattern of association between clinical form of vitiligo and disease-related variables in a Brazilian population. Dermatol Sci. 2012;65(1):63–7.Google Scholar
  63. 63.
    Al Refu K. Vitiligo in children: a clinical-epidemiologic study in Jordan. Pediatr Dermatol. 2012;29(1):114–5.PubMedGoogle Scholar
  64. 64.
    Uncu S, Yaylı S, Bahadır S, Okten A, Alpay K. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. Int J Dermatol. 2011;50(2):175–9.PubMedGoogle Scholar
  65. 65.
    Jin Y, Ferrara T, Gowan K, et al. Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation. J Invest Dermatol. 2012;132:1730–3.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Ben Ahmed M, Zaraa I, Rekik R, et al. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res. 2012;25:99–109.PubMedGoogle Scholar
  67. 67.
    Lin X, Tian H, Xianmin M. Possible roles of B lymphocyte activating factor of the tumour necrosis factor family in vitiligo autoimmunity. Med Hypotheses. 2011;76:339–42.PubMedGoogle Scholar
  68. 68.
    Levandowski CB, Mailloux CM, Ferrara TM, et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci U S A. 2013;110:2952–6.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Hann SK, Shin HK, Park SH, Reynolds SR, Bystryn JC. Detection of antibodies to melanocytes in vitiligo by western immunoblotting. Yonsei Med J. 1996;37:365–70.PubMedGoogle Scholar
  70. 70.
    Träger U, Sierro S, Djordjevic G, et al. The immune response to melanoma is limited by thymic selection of self-antigens. PLoS One. 2012;7:e35005.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Sanchez-Sosa S, Aguirre-Lombardo M, Jimenez-Brito G, Ruiz-Argüelles A. Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo. Clin Exp Immunol. 2013;173:179–83.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Horn TD, Abanmi A. Analysis of the lymphocytic infiltrate in a case of vitiligo. Am J Dermatopathol. 1997;19:400–2.PubMedGoogle Scholar
  73. 73.
    Jalel A, Yassine M, Hamdaoui MH. Oxidative stress in experimental vitiligo C57BL/6 mice. Indian J Dermatol. 2009;54:221–4.PubMedCentralPubMedGoogle Scholar
  74. 74.
    Liu L, Li C, Gao J, et al. Genetic polymorphisms of glutathione S-transferase and risk of vitiligo in the Chinese population. J Invest Dermatol. 2009;129:2646–52.PubMedGoogle Scholar
  75. 75.
    D’Osualdo A, Reed JC. NLRP1, a regulator of innate immunity associated with vitiligo. Pigment Cell Melanoma Res. 2012;25:5–8.PubMedGoogle Scholar
  76. 76.
    Ruiz-Argüelles A, Brito GJ, Reyes-Izquierdo P, et al. Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun. 2007;29:281–6.PubMedGoogle Scholar
  77. 77.
    Kumar R, Parsad D. Melanocytorrhagy and apoptosis in vitiligo: connecting jigsaw pieces. Indian J Dermatol Venereol Leprol. 2012;78:19–23.PubMedGoogle Scholar
  78. 78.
    Wu J, Zhou M, Wan Y, Xu A. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis. Mol Med Rep. 2013;7:237–41.PubMedCentralPubMedGoogle Scholar
  79. 79.
    Li K, Shi Q, Yang L, et al. The association of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D levels with generalized vitiligo. Br J Dermatol. 2012;167:815–21.PubMedGoogle Scholar
  80. 80.
    Xu X, Fu WW, Wu WY. Serum 25-hydroxyvitamin D deficiency in Chinese patients with vitiligo: a case-control study. PLoS One. 2012;7(12):e52778.PubMedCentralPubMedGoogle Scholar
  81. 81.
    Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010;62:937–41.PubMedGoogle Scholar
  82. 82.
    Silverberg NB. Atlas of cutaneous biodiversity. New York: Springer; 2012. 38p.Google Scholar
  83. 83.
    Ezzedine K, Lim HW, Suzuki T, Vitiligo Global Issue Consensus Conference Panelists, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25:E1–13.PubMedCentralPubMedGoogle Scholar
  84. 84.
    Ghosh S. Chemical leukoderma: what’s new on etiopathological and clinical aspects? Indian J Dermatol. 2010;55:255–8.PubMedCentralPubMedGoogle Scholar
  85. 85.
    Mazereeuw-Hautier J, Bezio S, Mahe E, Bodemer C, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: a prospective observational study. J Am Acad Dermatol. 2010;62(6):945–9.PubMedGoogle Scholar
  86. 86.
    Ezzedine K, Diallo A, Léauté-Labrèze C, Séneschal J, Prey S, Ballanger F, Alghamdi K, Cario-André M, Jouary T, Gauthier Y, Taieb A. Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. Br J Dermatol. 2012;166(3):539–44.PubMedGoogle Scholar
  87. 87.
    Hann SK, Kim YS, Yoo JH, Chun YS. Clinical and histopathologic characteristics of trichrome vitiligo. J Am Acad Dermatol. 2000;42:589–96.PubMedGoogle Scholar
  88. 88.
    Herane MI. Vitiligo and leukoderma in children. Clin Dermatol. 2003;21:283–95.PubMedGoogle Scholar
  89. 89.
    Ezzedine K, Gauthier Y, Léauté-Labrèze C, et al. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J Am Acad Dermatol. 2011;65:965–71.PubMedGoogle Scholar
  90. 90.
    Porter JR, Beuf AH. Racial variation in reaction to physical stigma: a study of degree of disturbance by vitiligo among black and white patients. J Health Soc Behav. 1991;32(2):192–204.PubMedGoogle Scholar
  91. 91.
    Lin X, Tang LY, Fu WW, Kang KF. Childhood vitiligo in China: clinical profiles and immunological findings in 620 cases. Am J Clin Dermatol. 2011;12(4):277–81.PubMedGoogle Scholar
  92. 92.
    Ducharme EE, Silverberg NB. Selected applications of technology in the pediatric dermatology office. Semin Cutan Med Surg. 2008;27(1):94–100.PubMedGoogle Scholar
  93. 93.
    Lee DY, Kim CR, Park JH, Lee JH. The incidence of leukotrichia in segmental vitiligo: implication of poor response to medical treatment. Int J Dermatol. 2011;50:925–7.PubMedGoogle Scholar
  94. 94.
    Pagovich OE, Silverberg JI, Freilich E, Silverberg NB. Thyroid abnormalities in pediatric patients with vitiligo in New York City. Cutis. 2008;81:463–6.PubMedGoogle Scholar
  95. 95.
    Iacovelli P, Sinagra JL, Vidolin AP, et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology. 2005;210:26–30.PubMedGoogle Scholar
  96. 96.
    Gey A, Diallo A, Seneschal J, Léauté-Labrèze C, Boralevi F, Jouary T, Taieb A, Ezzedine K. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br J Dermatol. 2013;168:756–61.PubMedGoogle Scholar
  97. 97.
    Prindaville B, Rivkees SA. Incidence of vitiligo in children with Graves’ disease and Hashimoto’s thyroiditis. Int J Pediatr Endocrinol. 2011;2011:18.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Palit A, Inamadar A. Childhood vitiligo. Indian J Dermatol Venereol Leprol. 2012;78:30–41.PubMedGoogle Scholar
  99. 99.
    Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, Macri GF, De Virgilio A, de Vincentiis M. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev. 2013;12:1033–8.PubMedGoogle Scholar
  100. 100.
    Cutolo M. Autoimmune polyendocrine syndromes. Autoimmun Rev. 2014;13(2):85–9.PubMedGoogle Scholar
  101. 101.
    Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014;31(3):309–18.PubMedGoogle Scholar
  102. 102.
    Bilgiç O, Bilgiç A, Akiş HK, Eskioğlu F, Kiliç EZ. Depression, anxiety and health-related quality of life in children and adolescents with vitiligo. Clin Exp Dermatol. 2011;36:360–5.PubMedGoogle Scholar
  103. 103.
    Choi S, Kim DY, Whang SH, et al. Quality of life and psychological adaptation of Korean adolescents with vitiligo. J Eur Acad Dermatol Venereol. 2010;24:524–9.PubMedGoogle Scholar
  104. 104.
    Bilgic O, Bilgic A, Akis HK, Eskioglu F, Kilic EZ. Depression, anxiety and health-related quality of life in children and adolescents with vitiligo. Clin Exp Dermatol. 2011;36:360–5.PubMedGoogle Scholar
  105. 105.
    Grau C, Silverberg NB. Vitiligo patients seeking depigmentation therapy: a case report and guidelines for psychological screening. Cutis. 2013;91(5):248–52.PubMedGoogle Scholar
  106. 106.
    Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol. 2004;51:760–6.PubMedGoogle Scholar
  107. 107.
    Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149:159–64.PubMedGoogle Scholar
  108. 108.
    Teulings HE, Overkamp M, Ceylan E, Nieuweboer-Krobotova L, Bos JD, Nijsten T, Wolkerstorfer AW, Luiten RM, van der Veen JP. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013;168:162–71.PubMedGoogle Scholar
  109. 109.
    Mikhail M, Wolchok J, Goldberg SM, Dunkel IJ, Roses DF, Silverberg NB. Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus. Arch Dermatol. 2008;144:560–1.PubMedGoogle Scholar
  110. 110.
    Silverberg NB. Recent advances in childhood vitiligo. Clin Dermatol. 2014;32:524–30.Google Scholar
  111. 111.
    Ismail SA, Sayed DS, Abdelghani LN. Vitiligo management strategy in Jeddah, Saudi Arabia as reported by dermatologists and experienced by patients. J Dermatolog Treat. 2014;25(3):205–11. Epub ahead of print.PubMedGoogle Scholar
  112. 112.
    Taieb A. Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res. 2011;25:9–13.PubMedGoogle Scholar
  113. 113.
    Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47:789–91.PubMedGoogle Scholar
  114. 114.
    Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol. 2003;139:571–4.PubMedGoogle Scholar
  115. 115.
    Silverberg JI, Silverberg NB. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color. J Drugs Dermatol. 2011;10:507–10.PubMedGoogle Scholar
  116. 116.
    Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139:581–5.PubMedGoogle Scholar
  117. 117.
    Ho N, Pope E, Weinstein M, et al. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1%vs. clobetasol propionate 0·05% in childhood vitiligo. Br J Dermatol. 2011;165:626–32.PubMedGoogle Scholar
  118. 118.
    Udompataikul M, Boonsupthip P, Siriwattanagate R. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. J Dermatol. 2011;38:536–40.PubMedGoogle Scholar
  119. 119.
    Berti S, Buggiani G, Lotti T. Use of tacrolimus ointment in vitiligo alone or in combination therapy. Skin Therapy Lett. 2009;14:5–7.PubMedGoogle Scholar
  120. 120.
    Bakos L, Bakos RM. Focal acne during topical tacrolimus therapy for vitiligo. Arch Dermatol. 2007;143:1223–4.PubMedGoogle Scholar
  121. 121.
    Köse O, Arca E, Kurumlu Z. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat. 2010;21:133–9.PubMedGoogle Scholar
  122. 122.
    Farajzadeh S, Daraei Z, Esfandiarpour I, et al. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol. 2009;26:286–91.PubMedGoogle Scholar
  123. 123.
    Hui-Lan Y, Xiao-Yan H, Jian-Yong F, et al. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol. 2009;26:354–6.PubMedGoogle Scholar
  124. 124.
    Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol. 1984;120:631–5.PubMedGoogle Scholar
  125. 125.
    Cockayne SE, Messenger AG, Gawkrodger DJ. Vitiligo treated with topical corticosteroids: children with head and neck involvement respond well. J Am Acad Dermatol. 2002;46:964–5.PubMedGoogle Scholar
  126. 126.
    Kwon HB, Choi Y, Kim HJ, Lee AY. The therapeutic effects of a topical tretinoin and corticosteroid combination for vitiligo: a placebo-controlled, paired-comparison, left-right study. J Drugs Dermatol. 2013;12:e63–7.PubMedGoogle Scholar
  127. 127.
    Travis LB, Silverberg NB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol. 2004;21(4):495–8.PubMedGoogle Scholar
  128. 128.
    Veith W, Deleo V, Silverberg N. Medical phototherapy in childhood skin diseases. Minerva Pediatr. 2011;63:327–33.PubMedGoogle Scholar
  129. 129.
    Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol. 1993;32:753–7.PubMedGoogle Scholar
  130. 130.
    Kanwar AJ, Dhar S, Dawn G. Oral minipulse therapy in vitiligo. Dermatology. 1995;190:251–2.PubMedGoogle Scholar
  131. 131.
    Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013;17:259–68.PubMedGoogle Scholar
  132. 132.
    Al Aboosi M, Ajam ZA. Oral photochemotherapy in vitiligo: follow-up, patient compliance. Int J Dermatol. 1995;34:206–8.PubMedGoogle Scholar
  133. 133.
    Hann SK, Im S, Bong HW, Park YK. Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J Am Acad Dermatol. 1995;32:943–8.PubMedGoogle Scholar
  134. 134.
    Khalid M, Mujtaba G, Haroon TS. Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. Int J Dermatol. 1995;34:203–5.PubMedGoogle Scholar
  135. 135.
    Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 2000;42:245–53.PubMedGoogle Scholar
  136. 136.
    Hallaji Z, Ghiasi M, Eisazadeh A, Damavandi MR. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2012;28:115–9.PubMedGoogle Scholar
  137. 137.
    Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274–8.PubMedGoogle Scholar
  138. 138.
    Percivalle S, Piccinno R, Caccialanza M, Forti S. Narrowband ultraviolet B phototherapy in childhood vitiligo: evaluation of results in 28 patients. Pediatr Dermatol. 2012;29:160–5.PubMedGoogle Scholar
  139. 139.
    Majid I. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. Photodermatol Photoimmunol Photomed. 2010;26:230–4.PubMedGoogle Scholar
  140. 140.
    Bayoumi W, Fontas E, Sillard L, et al. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. Br J Dermatol. 2012;166:208–11.PubMedGoogle Scholar
  141. 141.
    Patel N, O’Haver J, Hansen RC. Vitiligo therapy in children: a case for considering excimer laser treatment. Clin Pediatr (Phila). 2010;49:823–9.Google Scholar
  142. 142.
    Do JE, Shin JY, Kim DY, Hann SK, Oh SH. The effect of 308nm excimer laser on segmental vitiligo: a retrospective study of 80 patients with segmental vitiligo. Photodermatol Photoimmunol Photomed. 2011;27(3):147–51.PubMedGoogle Scholar
  143. 143.
    Kato H, Furuhashi T, Ito E, et al. Efficacy of 1-mm minigrafts in treating vitiligo depends on patient age, disease site and vitiligo subtype. J Dermatol. 2011;38:1140–5.PubMedGoogle Scholar
  144. 144.
    Matsuzaki K, Kumagai N. Treatment of vitiligo with autologous cultured keratinocytes in 27 cases. Eur J Plast Surg. 2013;36:651–6.PubMedCentralPubMedGoogle Scholar
  145. 145.
    Kim BS, Kim JM, Kim WJ, et al. Circumcised foreskin may be useful as a donor tissue during an autologous, non-cultured, epidermal cell transplantation for the treatment of widespread vitiligo. J Dermatol. 2012;39:558–9.PubMedGoogle Scholar
  146. 146.
    Yao L, Li SS, Zhong SX, et al. Successful treatment of vitiligo on the axilla in a 5-year-old child by cultured-melanocyte transplantation. J Eur Acad Dermatol Venereol. 2012;26:658–60.PubMedGoogle Scholar
  147. 147.
    Linthorst Homan MW, Spuls PI, et al. A randomized comparison of excimer laser versus narrow-band ultraviolet B phototherapy after punch grafting in stable vitiligo patients. J Eur Acad Dermatol Venereol. 2012;26:690–5.PubMedGoogle Scholar
  148. 148.
    Tedeschi A, Dall’Oglio F, Micali G, Schwartz RA, Janniger CK. Corrective camouflage in pediatric dermatology. Cutis. 2007;79:110–2.PubMedGoogle Scholar
  149. 149.
    Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013;149:68–73.PubMedGoogle Scholar
  150. 150.
    El-Mofty M, Mostafa W, Youssef R, El-Fangary M, El-Ramly A, Mahgoub D, Fawzy M, El-Hawary M. BB-UVA vs. NB-UVB in the treatment of vitiligo: a randomized controlled clinical study (single blinded). Photodermatol Photoimmunol Photomed. 2013;29:239–46.PubMedGoogle Scholar
  151. 151.
    Taïeb A, Seneschal J. Targeting iHSP 70 in vitiligo: a critical step for cure? Exp Dermatol. 2013;22:570–1.PubMedGoogle Scholar
  152. 152.
    O’Callaghan F, Shiell A, Osborne J, Martyn C. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;352:318–9.Google Scholar
  153. 153.
    Krueger DA, Northrup H, on behalf of the International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:255–65.PubMedCentralPubMedGoogle Scholar
  154. 154.
    Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243–54.PubMedCentralPubMedGoogle Scholar
  155. 155.
    European Chrosome 16 tuberous sclerosis consortium: identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305–15.Google Scholar
  156. 156.
    Van Slegtenhorst M, deHoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805–8.PubMedGoogle Scholar
  157. 157.
    Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I. Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. PLoS One. 2013;8(5):e63910.PubMedCentralPubMedGoogle Scholar
  158. 158.
    Torrelo A, Hadj-Rabia S, Colmenero I, Piston R, Sybert VP, Hilari-Carbonell H, Hernández-Martín A, Ferreres JC, Vañó-Galván S, Azorín D, de Salamanca JE, Requena L, Bodemer C, Happle R, García-Patos V, Fraitag S. Folliculocystic and collagen hamartoma of tuberous sclerosis complex. J Am Acad Dermatol. 2012;66(4):617–21.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Joni M. Mazza
    • 1
  • Candrice Heath
    • 1
  • Nanette B. Silverberg
    • 1
  1. 1.Department of DermatologyMt. Sinai St. Luke’s-Roosevelt Hospital CenterNew YorkUSA

Personalised recommendations